A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Official Title: A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

NCT02564198
Goldman, Stewart, MD
Interventional
Yes

Contact Information:

Stewart Goldman, MD

Principal Investigator

312.227.4090